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Although aneuploidy is a hallmark of
cancer, our understanding of its contri-
butions to cancer initiation and progres-
sion remains limited.
Aneuploidy is physiologically associated
with drastic cellular stress, but paradoxi-
cally favors tumor progression. Signifi-
cant progress has been achieved over
recent years in deciphering how aneu-
ploid cancer cells self-adapt to promote
tumorigenesis.Aneuploidy, the gain or loss of chromosomes in a cell, is a hallmark of cancer.
Although our understanding of the contribution of aneuploidy to cancer initiation
and progression is incomplete, significant progress has been made in uncovering
the cellular consequences of aneuploidy and how aneuploid cancer cells self-
adapt to promote tumorigenesis. Aneuploidy is physiologically associated with sig-
nificant cellular stress but, paradoxically, it favors tumor progression. Although
more common in solid tumors, different forms of aneuploidy represent the initiating
oncogenic lesion in patients with B cell acute lymphoblastic leukemia (B-ALL),
making B-ALL an excellent model for studying the role of aneuploidy in tumori-
genesis. We review the molecular mechanisms underlying aneuploidy and
discuss its contributions to B-ALL initiation and progression.Different forms of aneuploidy represent
the initiating oncogenic lesion in ~35%
of patients with B-cell acute lympho-
blastic leukemia (B-ALL), especially in
childhood B-ALL.
Hyperdiploid B-ALL cells display a typi-
cal aneuploid-stress signature in which
mitotic and chromosomal segregation
defects are associated with impair-
ments of the condensin complex and
the aurora B kinase/chromosomal
passenger complex (CPC), leading to
cohesion defects and mitotic slippage.
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The gain or loss of whole chromosomes, termed aneuploidy (see Glossary), was identified as
a distinct feature of cancer cells more than a century ago by the German zoologist Theodor
Boveri [1], and is now recognized as a major genomic insult in human cancers [2,3]. Aneuploidy
is observed more frequently than any other oncogenic or tumor-suppressor mutation, and is
found in ~90% of solid tumors and ~60% of hematological malignancies [4]. High-resolution,
genome-wide analysis has revealed that ~25% of the genome in each cancer cell is affected
by either chromosome-arm or whole-chromosome copy-number alterations [5]. Importantly,
although recent studies have regarded both chromosome-arm gains and losses as
aneuploidy, these are generated by different mechanisms. Thus, according to the classical
definition of aneuploidy, we hereafter use the term 'aneuploidy' to refer to whole-chromosome
gains and losses.
Despite its high incidence, our understanding of the contribution of aneuploidy to cancer initiation
and progression is limited for several reasons. First, large chromosomal changes lead to alterations
in hundreds of genes and/or pathways, making it challenging to precisely identify those genes
involved in tumorigenesis. Second, aneuploidy is often associated with chromosome instability
(CIN) and/ormicrosatellite instability (MIN) [6,7] that generate heterogeneous aneuploid karyo-
types, making it difficult to distinguish the alterations that drive cancer growth from the numerous,
apparently random, genetic alterations that occur during tumorigenesis. Third, aneuploidy is highly
dependent on the cellular context and can both promote and inhibit tumor development in a tissue-
specific manner [2]. Indeed, specific chromosome gains and losses have been shown to be linked
to specific cell types and tumors [8,9]. Finally, the generation of models with specific aneuploidies
remains technically challenging despite recent advances in microcell-mediated cell transfer [10]
and in Cre/loxP [11] and CRISPR/Cas9 technology [12].
Given the widespread aneuploidy found in cancer, there has been long-standing debate on
whether it is the cause or consequence of cancer. Because cancer cells are often defective inTrends in Cancer, January 2021, Vol. 7, No. 1 https://doi.org/10.1016/j.trecan.2020.08.008 37
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arises as a consequence of disruption of these pathways [13,14]. Another possibility is that
aneuploidy per se acts as a tumor-initiating event. In this line, it was shown that introduction of
specific chromosomes into cells induces replication stress and further genomic instability [15],
which may trigger cell transformation [11,16–18]. Of note, aneuploidy has been observed in
some preneoplastic conditions such as Barrett’s esophagus [19]. In addition, Down syndrome
(DS) individuals harboring constitutional trisomy of chromosome 21 have a 200-fold higher risk of
developing hematological malignancies [20]. Aneuploidy may clearly exert a tumor-promoting
role in some cancers.
We review here the cellular and molecular mechanisms underlying aneuploidy, and discuss
recent findings highlighting how aneuploidy contributes to the origin and progression of B-cell
acute lymphoblastic leukemia (B-ALL). B-ALL represents an excellent model for studying the
role of aneuploidy in tumor development because frequent chromosome gains and losses are
observed as the sole genomic abnormalities in aneuploid B-ALL.
Aneuploidy Is Caused by Chromosome Segregation Defects
The karyotype of most aneuploid tumors is within the range of diploid cells (46 chromosomes [4]),
suggesting that chromosome imbalances occur largely through sequential losses and gains of
chromosomes through CIN from an initial diploid state or by chromosome losses after
endoreduplication of genetic material. Mechanisms of CIN include those that reduce mitotic
fidelity leading to chromosome segregation defects [21].
Improper Kinetochore–Microtubule Attachments
During prometaphase, nuclear envelope breakdown allows chromosomes to attach tomicrotubule-
based 'spindles' via kinetochores (Figure 1). During metaphase, chromosomes are concentrated
in a region at the mid-plane of the bipolar mitotic spindle known as the metaphase plate. The back-
to-back geometry of sister kinetochores on each chromosome favors the attachment of each chro-
matid to microtubules arising from opposite poles (amphitelic attachments), thus allowing proper
chromosome bi-orientation and segregation [22]. However, the stochastic nature of kinetochore–
microtubule attachments frequently leads to chromosome misattachments to the spindle [23],
such as syntelic, monotelic, and merotelic attachments (Figure 1). These attachment defects
occur naturally in early mitosis and, in healthy cells, they are detected and corrected before ana-
phase onset by a system that includes different tension-sensing factors, including aurora B kinase
and Mps1, to ensure faithful chromosome segregation [24]. Merotelic attachments are the most
common cause of chromosome segregation errors because they are less likely to be detected by
these factors and are often not corrected in cancer cells [21,25]. The persistence ofmerotelic attach-
ments in human cancer cells is mediated by two nonexclusive mechanisms – a decreased rate of
error correction and an increased rate of merotely. Notably, some cancer cell lines display
hyperstable merotelic kinetochore–microtubule attachments in early mitosis [25], suggestive of
inherent defects in correcting erroneous kinetochore–microtubule attachments. Accordingly, de-
fects in several centromere/kinetochore proteins have been observed to reduce chromosome
segregation efficiency by increasing the frequency of merotelic attachments and lagging chro-
mosomes in anaphase [26,27]. However, mutations of kinetochore proteins in cancer are
rare, presumably because these proteins are essential for life. However, imbalances in the
levels of these proteins might act dominantly [23]. Correspondingly, other mechanisms such as
epigenetic abnormalities in centrochromatin, such as loss of histone H3 lysine 4 dimethylation,
that is typically found at the core centromere interspersed with the centromere-specific histone
H3 CENP-A, were shown to lead to abnormal kinetochore protein levels resulting in chromosome
mis-segregation [28,29].38 Trends in Cancer, January 2021, Vol. 7, No. 1
Glossary
Aneuploidy: gain or loss of one or more
chromosomes resulting in an unbalanced
chromosome number that is not an exact
multiple of the haploid complement.
Bridge-fusion-breakage cycle: a
mechanism of chromosome instability in
which broken ends from different
chromatids fuse, leading to the
formation of a dicentric chromosome.
This chromosome bridge breaks apart in
mitosis as centromeres are pulled in
opposite directions, generating broken
ends that can reinitiate the cycle.
Centrosomes: microtubule organizing
centers in metazoans; they consist of a
pair of cylindrical centrioles surrounded by
a matrix of proteins called the
pericentriolar material, where most
centrosome-associated proteins localize.
Chromosomal passenger complex
(CPC): a heterotetrameric protein
complex consisting of an enzymatic
component aurora B kinase together
with three regulatory components:
INCENP (inner centromere protein),
survivin, and borealin. The CPC
dynamically localizes to different
subcellular localizations throughout
mitosis to regulate key events such
as kinetochore–microtubule
attachments, activation of the SAC,
and assembly and maintenance of
the outer kinetochore.
Chromosome instability (CIN):
persistent gains and losses of
chromosomes during cell division. It is
important to underscore the difference
between aneuploidy (the 'state' of the
karyotype) and CIN (the 'rate' of
karyotypic changes).
Chromothripsis: a mutational process
by which up to thousands of clustered
chromosomal rearrangements occur
following the formation of micronuclei
containing mis-segregated
chromosomes.
Cohesin: a multiprotein ring-shaped
complex that maintains replicated sister
chromatids together from S-phase until
anaphase onset.
Euploidy: a chromosome number that
is an exact multiple of the haploid
complement (n). It includes diploidy,
triploidy, tetraploidy, and polyploidy.
Ploidies other than diploidy decrease the
fitness of cells but, compared with
aneuploid cells, polyploid cells are
relatively fit because their gene
expression remains balanced and they
therefore represent a more stable state
than any aneuploidy.
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Figure 1. Mechanisms of Chromosome Mis-Segregation. Newly replicated chromatids are held together by cohesin,
a multiprotein complex that in humans is composed of four subunits: two structural maintenance of chromosomes (SMC)
ATPases (SMC1 and SMC3), the kleisin sister-chromatid cohesion protein 1 (RAD21), and stromal antigen (SA). During
prophase, the bulk of cohesin is removed from chromosome arms by Pds5–WAPL and only remains at centromeres that
are protected by shugoshin 1 (Sgo1). In prometaphase, kinetochore–microtubule attachments are initiated, including
amphitelic attachments (sister kinetochores are attached to microtubules from opposite poles), syntelic attachments (both
(Figure legend continued at the bottom of the next page.)
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Kinetochore: a large protein complex
that assembles at centromeres and
binds to microtubules and directs
chromosome segregation [90].
Li–Fraumeni syndrome: a rare
autosomic dominant disorder caused by
mutations in the TP53 gene; the
syndrome is associated with an
increased risk of developing different
types of cancer.
Microsatellite instability (MIN): clonal
changes in the number of repeated DNA
nucleotide units in microsatellite
sequences. It arises in some tumors
owing to inactivation of mismatch repair
genes.
Mitosis: a highly orchestrated cellular
process for faithful segregation of
replicated chromosomes into two
identical daughter cells.
Spindle-assembly checkpoint
(SAC): an evolutionarily conserved
surveillance mechanism that detects the
presence ofmisattached kinetochores in
mitosis and pauses division until all pairs
of sister chromatids achieve the
bioriented geometry.
Trends in CancerDefects in Chromosome Cohesion
In eukaryotes, newly duplicated sister chromatids are held together by cohesin [30]. Cohesin is
also important to ensure the back-to-back orientation of kinetochores that facilitate chromosome
amphitely (Figure 1), and is involved in other fundamental cellular processes such as DNA repair
and transcription regulation [31]. Cohesin is removed from chromosomes in two stages during
cell division to allow physical separation of the sister chromatids and accurate transfer of the
genetic material into the two daughter cells. The bulk of cohesin is removed from the chromo-
some arms during early mitosis in a process driven by the cohesin-associated factor Pds5 and
the cohesin-release factor WAPL that form the Pds5–WAPL complex (Figure 1). Residual cohesin
is concentrated at centromeres where it is protected from removal by shugoshin-1 (from
the Japanese 'guardian spirit'), resulting in the classical X-shaped mitotic chromosome [32]
(Figure 1). Once all chromosomes have aligned at the metaphase plate, the protease separase
removes centromeric cohesion and triggers anaphase onset, allowing separation of the sister chro-
matids to opposite spindle poles (Figure 1) [30,33]. Defective sister chromatid cohesion can result
in chromosome mis-segregation and aneuploidy, and both mutations and abnormal expression of
cohesin-related genes have been identified in different human cancers [34]. Given the essential role
of cohesin in genome stability and transcription regulation, cohesion dysfunction might affect
tumorigenesis in different ways; further studies will be necessary to shed light on the functional
importance of mutations in cohesin and its interacting partners.
Defective Spindle-Assembly Checkpoint
Eukaryotic cells have developed an evolutionarily conserved surveillance mechanism to prevent
chromosome mis-segregation as a result of erroneous kinetochore–microtubule attachments,
termed the spindle-assembly checkpoint (SAC). The SAC pathway serves to restrain the
protease separase, which cleaves the cohesin complex in anaphase (Figure 1). Impairment of the
SAC allows precocious anaphase onset, and consequently significantly increases the frequency
of chromosome mis-segregation [35]. Complete SAC ablation leads to massive chromosome
mis-segregation and catastrophic cell death in cell lines [35,36] and is embryonic lethal in mice
[37], but not in Drosophila, where chromosome attachment to the mitotic spindle occurs extremely
rapidly [38]. By contrast, heterozygous mutations in different SAC proteins induce aneuploidy and
tumorigenesis in mice [39–41]. Of note, mutations in BUB1B, that encodes the SAC protein
BubR1, cause mosaic variegated aneuploidy in humans – a rare and recessive syndrome that is
associated with mosaic aneuploidy and predisposition to cancer development [41].
Supernumerary Centrosomes
Centrosomes are responsible for the formation of the mitotic spindle that is needed for proper
chromosome segregation [42]. Coordination of the duplication and segregation cycles of centro-
somes is essential to prevent chromosome segregation defects, because the number of centro-
somes in a cell determines the number of spindle poles [43]. Duplication of the centrosome that is
present in a G1 cell begins during S phase. In early mitosis the duplicated centrosomes nucleatesister kinetochores are attached to microtubules from the same pole), monotelic attachments (only one sister kinetochore is
attached to the spindle), and merotelic attachments (both sister kinetochores are simultaneously attached to microtubules
emanating from the same pole). Erroneous attachments are sensed by aurora B (AURKB) and Mps1 kinases that retain
the mitotic checkpoint complex (Bub proteins, Mad2, and Cdc20) at unattached kinetochores and keep the spindle
assembly checkpoint (SAC) activated, blocking the activity of the anaphase-promoting complex/cyclosome (APC/C). In
metaphase, the tension established by amphitelic attachments causes the chromosomes to align at the metaphase plate
Correct kinetochore–microtubule attachments inactivate the SAC and allow APC/C activation, releasing separase to
cleave cohesin rings at centromeres and promoting anaphase onset. Merotelic attachments are usually not sensed by
aurora B, and these chromosomes frequently lag behind in anaphase, giving rise to either euploid or aneuploid daughte
cells. Lagging chromosomes can be trapped in the cleavage furrow in cytokinesis, leading to chromosome breakage, o
they segregate intact to a daughter cell where they can eventually encapsulate as a micronucleus. Abbreviations: PCM
pericentriolar material; Ub, ubiquitin.





OPEN ACCESSthe spindle microtubules and, later on in mitosis, the centrosomes from opposite spindle poles
segregate to the daughter cells together with a complete set of chromosomes. An abnormal
number of centrosomes can arise from defects in the centrosome replication cycle, segregation
failure during mitosis, or cell fusion, leading to genome doubling and polyploidy. Remarkably,
several observations support the hypothesis that polyploid cells represent early steps in tumor
formation because centrosome duplication represents a source of merotelic attachments leading
to chromosome mis-segregation [44–46].
Consequences of Aneuploidy and the 'Aneuploidy Paradox' in Cancer
The deleterious effects of aneuploidy in physiology are well established from yeast to mammalian
cells [16,47]. Aneuploidy is often lethal in multicellular organisms, and the few aneuploidies that do
not cause lethality can reduce growth and trigger developmental abnormalities, leading to a
substantial fitness cost under most circumstances [2]. Indeed, aneuploid mice generated by
chromosome transfer die in utero at early stages [16]. Aneuploid cells share a set of phenotypes
that are collectively known as the 'aneuploidy-stress phenotype' [48], which includes specific
cellular responses such as lower proliferation rates, genetic andmetabolic stress, and organismal
effects including immune system activation (Box 1).
Despite the detrimental consequences of aneuploidy for cell fitness, the fact that it is a strikingly
common feature in cancer creates a paradox in terms of its contribution to tumorigenesis, the
so-called 'aneuploidy paradox' [2]. It is now clear that the effects of aneuploidy on tumorigenesis
are much more complex than was initially proposed. Aneuploidy and CIN can act both as tumor-
suppressors and tumor-initiators depending on the context [2,18]. A pan-cancer genomic
analysis based on the potency and distribution of oncogenes and tumor-suppressor genes
suggested that cumulative haploinsufficiencies and triplosensitivities drive aneuploidy patternsBox 1. Aneuploidy-Stress Phenotype
Cellular Effects of Aneuploidy
The most evident effect of aneuploidy is a reduction in cell proliferation and delayed cell-cycle progression at the G1–S
transition [16,47,71]. Of note, the proliferation defects are not observed in aneuploid mouse embryonic stem cells or human
pluripotent stem cells [17,72,73], suggesting a variable tolerance to aneuploidy depending on the developmental stage of
the cell. Lower proliferation rates are most likely a response to other cellular stresses associatedwith aneuploidy, such as gene
expression and proteotoxic stresses. In addition, aneuploid cells have a characteristic gene expression signature in which gene
expression networks are globally disturbed, similarly to the environmental stress response in yeast [47]. In mammalian cells, the
aneuploidy-stress response involves the conserved downregulation of pathways involved in nucleic acid metabolism, including
replication, DNA repair, transcription, and RNA processing, as well as upregulation of pathways associated with autophagy,
lysosomal pathways, and membrane metabolism, metabolic pathways such as glycolysis, and pathways associated with
the inflammatory response [71]. The increased gene expression triggers proteotoxic stress as cells attempt to cope with the
unbalanced excess of proteins generated by additional chromosome numbers. Proteotoxic stress is characterized by impaired
protein folding, activation of degradation pathways, and accumulation of cytoplasmic protein aggregates with consequent
accumulation of autophagosomes [74,75]. These pathways allow aneuploid cells to maintain protein homeostasis against a
background of elevated gene expression. In addition to metabolic stresses, aneuploidy generates further genomic instability,
leading to cancer genome evolution and adaptation. Genomic instability in aneuploid cells is triggered by different mechanisms
such as replication stress [15], chromosome bridge-fusion-breakage cycles [76,77], and chromothripsis [78].
Organismal/Physiological Effects
Aneuploidy and CIN activate the innate immune response through the cGAS–STING pathway (cyclic GMP-AMP synthase–
stimulator of interferon genes), a cellular defense against viral infection [79,80]. The cGAS–STING pathway detects
DNA double-strand breaks (DSBs) that leak from micronuclei into the cytoplasm and induce the transcriptional activa-
tion of inflammatory pathways, such as type I interferon signaling and the senescence-associated secretory phenotype
(SASP), thus providing a link between chromosome mis-segregation, aneuploidy, and innate immune signaling [80].
Indeed, the type I interferon pathway is consistently upregulated in aneuploid mammalian cells, and the expression
levels of proinflammatory cytokines increase upon chromosome mis-segregation [79,80]. Thus, aneuploidy triggers
signals for cell self-elimination that may serve as a means for cancer cell clearance.
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specific [9], and this may explain the tumor type-specificity of the observed patterns of chromo-
some gains and losses. Collectively, these data highlight the balance between the deleterious and
beneficial consequences of aneuploidy and CIN during the early steps of tumor evolution.
Aneuploidy in Hematological Neoplasms
Dramatically different biases of individual chromosome gains and losses have been reported
between solid tumors and hematological neoplasms, and these could reflect their fundamentally
different etiologies [4]. Whereas solid tumors preferentially lose chromosomes, this relationship is
not so clear in hematological neoplasms, which show a more balanced rate of chromosome
gains and losses [4]. Notably, the most frequently gained chromosome in hematological
neoplasms is chromosome 21, which has a clear bias towards loss in solid tumors. Consistently,
patients with DS, with constitutional trisomy 21, have a >200-fold increased susceptibility to
hematological neoplasms, including acute megakaryocyte-erythroid leukemia and B-ALL, but
appear to be protected from solid tumors [50]. Importantly, trisomy 21 and its mouse homolog
(trisomy 16) have been shown to perturb the development of hematopoietic stem and progenitor
cells (HSPCs), specifically B lymphoid differentiation [20,51,52]. These data suggest that trisomy
21 influences cell-autonomous differentiation and transformation phenotypes in progenitor B
cells, thus linking specific aneuploidies to the development of hematological neoplasms.
Because hematological neoplasms are characterized by the presence of recurrent chromosomal
abnormalities, cytogenetic studies at diagnosis remain essential to (i) confirm clonality, (ii) classify
patients based on World Health Organization (WHO)-defined subgroups, and (iii) stratify patients
according to their prognosis to determine the most suitable treatment (revised international prog-
nostic scoring system, IPSS-R) [53]. Beyond structural chromosome abnormalities, aneuploidy is
frequent in some hematological neoplasms and is associated with specific clinical outcomes
(Table 1). Although it is generally challenging to define which chromosomal abnormality represents
the primary change, chromosome gains and losses are mostly accompanied by additional cytoge-
netic aberrations that reflect disease progression in most hematological neoplasias. Nevertheless,
aneuploidy represents the primary event in some hematological neoplasms (Table 1), where ALLTable 1. Main Aneuploidy Cytogenetic Abnormalities in Hematological Neoplasmsa
Neoplasm Cytogenetic alterations Clinical outcome Refs
Chronic myelomonocytic leukemia (CMML) −Y Favorable [81]
+8, CK Poor
Myelodysplastic syndromes (MDS) −Y Very favorable [53]
−7b Poor
CK Very poor
Acute myeloblastic leukemia (AML) −5b, −7, +8, −17 or abn(17p), CK, MK Poor [82]
Chronic lymphocytic leukemia (CLL) +12b, +18 NPA [83]
Multiple myeloma (MM) +1, +3, +7, +11, +15 NPA [84,85]
Non-Hodgkin lymphoma (NHL) +3, +5, +7, +12, +18 NPA [86]
Myeloproliferative neoplasms (MPN) -7b, +8b, +9b, −Yb NPA [53]
Acute lymphoblastic leukemia (ALL) +21, hyperdiploidy (>50 chr)b Favorable [87,88]
Hypodiploidy (<40 chr)b Poor
aAbbreviations: abn, abnormality; chr, chromosomes; CK, complex karyotype; del, deletion; MK, monosomal karyotype;
NPA, no prognosis associated.
bAs a single abnormality.
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cytogenetic abnormalities (Box 2). The fact that chromosome gains and losses represent the unique
cytogenetic abnormality in most aneuploid B-ALL cases makes this an excellent model for studying
the pathogenic effects of aneuploidy on the initiation and progression of hematological cancers.
Etiology of Aneuploidy in Childhood B-ALL
Genomic studies mapping the temporal relationship between chromosomal gains or losses and
specific mutations in aneuploid chromosomes of B-ALL have revealed that aneuploidies arising
in utero are the initiating event in both hyperdiploid and hypodiploid childhood B-ALL [54,55].
These findings are consistent with studies showing that hyperdiploidy is present at birth, as
shown by genetic analysis of monozygotic twins with concordant and discordant high hyperdiploid
(HeH) B-ALL [56], the presence of hyperdiploid cells in cord blood samples [57], and the identifica-
tion of clonotypic IGH rearrangements in Guthrie cards (neonatal blood tests that are also known as
'heel-prick tests') from patients who later developed HeH-B-ALL [58]. Overall, these data strongly
suggest that aneuploidies are early initiating events acquired prenatally during fetal hematopoiesis,
as has been observed for other common reciprocal translocations in B-ALL, and also that a
secondary postnatal mutational event is necessary to promote leukemia development [59,60].
This requirement for secondary cooperating oncogenic insults is suggested by the variable post-
natal latency period of the disease and by the inability of common B-ALL fusion genes to promote
leukemia in either transgenic mice per se [61] or human HSPCs [62]. Accordingly, aneuploid B-ALL
cases typically have recurrent secondary mutations or copy-number alterations involving genes
such as CDKN2A, PAX5, IKZ1, and ETV6, as well as mitogen-activated protein kinase (MAPK)
signaling pathway genes (RAS, FLT3, and PTPN11) and histone modifiers [63,64].
The cellular and molecular mechanisms leading to aneuploidy in B cell progenitors are largely
unknown because the aberrant mitosis that generates the gross chromosome gains and lossesBox 2. Aneuploidies in B Cell ALL
Aneuploidies are common cytogenetic abnormalities in B-ALL, particularly in pediatric cases that account for ~30% of
B-ALL cases. The most frequent aneuploidies are hyperdiploid karyotypes, generally with several chromosome gains,
and these represent the largest cytogenetic subgroup in childhood B-ALL (25–30% of cases) [67]. Hyperdiploid B-ALL
is classified according to the chromosome gains into low-hyperdiploid (HeL-B-ALL), with 47–50 chromosomes; high-
hyperdiploid (HeH-B-ALL), with 51–67 chromosomes; and near-triploid/tetraploid, with >67 chromosomes (Figure IA–
C). Among hyperdiploid B-ALL cases, the most common group is HeH-B-ALL, which is associated with a favorable
prognosis and has a long-term overall survival (OS) of >90% [67]. Chromosome gains in B-ALL are not random, and
HeH-B-ALL shows preferential gains of chromosomes 4, 6, 10, 14, 17, 18, 21, and X. Further research will be neces-
sary to establish the individual contributions of each chromosome gain in both leukemia origin/initiation and (sub)clonal
intratumor heterogeneity.
Although HeH-B-ALL is themost common aneuploidy in childhood B-ALL, chromosome losses are also observed and are
classified as hypodiploid B-ALL, which represents <10% of patients with B-ALL [89]. Based on the number of chromo-
some losses, hypodiploid B-ALL cases are classified as high-hypodiploid (HoH-B-ALL), with 40–45 chromosomes;
low-hypodiploid (HoL-B-ALL), with 30–40 chromosomes (Figure ID); and near-haploid (Figure IE), with <30 chromosomes.
Most hypodiploid cases are HoH-B-ALL, but this group is genetically heterogeneous and does not have a clear prognostic
value. By contrast, HoL-B-ALL and near-haploid B-ALL, that account for ~2% of pediatric B-ALL cases, have an important
prognostic value but an extremely dismal prognosis (5 year OS of <25%) [89]. Similarly to hyperdiploid B-ALL, cases of
hypodiploid B-ALL display a preferential loss of chromosomes. In near-haploid B-ALL, retained disomies principally com-
prise chromosomes X/Y, 8, 10, 14, 18, and 21, whereas HoL-B-ALL shows preferential retention of disomies X/Y, 1, 5, 6,
8, 10, 11, 14, 18, 19, 21, and 22. Half of all patients with HoL-ALL frequently harbor 'inherited' TP53mutations, suggesting
that TP53-mutated HoL-B-ALL is a clinical evolution of Li–Fraumeni syndrome [64]. Notably, half of all hypodiploid B-ALL
cases show chromosomal doubling in the hypodiploid clone, resulting in clones with 50–78 chromosomes (Figure ID). The
doubled clones frequently represent the major leukemic clone at diagnosis, leading to 'masked-hypodiploidy' [89], which
is clinically challenging because these patients could be erroneously classified and be treated as hyperdiploid B-ALL while
being at high risk of treatment failure.
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Figure I. Aneuploid Karyotype Configurations Found in B-ALL. (A) G-banded karyotype of pseudodiploid B-ALL
blasts, where the only aneuploidy observed is +21. (B) G-banded karyotype of high-hyperdiploid B-ALL blasts. (C) R-banded
karyotype of near-tetraploid B-ALL blasts. (D) G-banded karyotype of low-hypodiploid B-ALL blasts (above) and a doubled-up
clone observed in the same patient sample with 74 chromosomes (below). Both clones were seen at disease presentation. (E)
R-banded karyotype of near-haploid B-ALL blasts. Abbreviation: B-ALL, B cell acute lymphoblastic leukemia; mar, structurally
abnormal marker chromosome in which no part can be identified.
Trends in Cancerin aneuploid B-ALL cannot be directly observed. The evidence for the cellular mechanisms
leading to aneuploid B-ALL is thus purely circumstantial. Studies of microsatellite sequence allelic
ratios in tetrasomic chromosomes and uniparental disomies (UPDs) in HeH-B-ALL cases strongly
suggest that hyperdiploid karyotypes arise as a result of simultaneous chromosome gains in a
single abnormal mitosis in most cases (~70%), or by chromosome losses from a tetraploid inter-
mediate (~30%) [65]. However, the cellular mechanisms leading to these mitotic defects remain
unknown.44 Trends in Cancer, January 2021, Vol. 7, No. 1
Outstanding Questions
Is there a common pathogenic
mechanism that is shared between
hyperdiploid and hypodipoid B-ALL?
What is the contribution of mitotic and
chromosome segregation defects to the
origin and progression of aneuploidy in
B-ALL?
What are the precise cellular and
molecular mechanisms that underlie
disease initiation and progression in
aneuploid subtypes of B-ALL?
What secondary alterations are
necessary (if any) to develop leukemia
in aneuploid B-ALL?
What is the contribution of each
chromosome gain or loss in both
leukemia initiation and progression?
Are chromosome-number alterations
stochastic or hierarchical?
Does intratumor heterogeneity contribute
to progression of aneuploidy B-ALL?
Why is aneuploidy preferentially observed
in pediatric B-ALL rather than in adult
B-ALL or acute myeloid leukemia
(AML)? Is there a developmental link
between aneuploidy and B cell
leukemia?
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OPEN ACCESSWhole-genome sequencing analyses in large cohorts of patients with aneuploid B-ALL have not
identified recurrent mutations or defects in genes associated with mitosis or cell division that
could explain the causative mechanisms for these aneuploidies in B cell progenitors [63,64].
However, no studies on the mitotic mechanisms involved in aneuploid B-ALL have been per-
formed. We recently reported the first and most comprehensive analysis of mitotic progression
of HeH-B-ALL using primary blasts and primograft-derived xenograft models [66]. The studies
revealed that hyperdiploid B-ALL blasts show a delay in early mitosis in prometaphase as a result
of defects in chromosome alignment that ultimately lead to chromosome segregation errors, as
observed by the presence of a higher frequency of anaphase bridges and lagging chromosomes
in late mitosis compared with non-hyperdiploid B-ALL samples. Accordingly, we observed
karyotype variability in HeH-B-ALL samples with a major clone and a series of smaller clones,
suggesting a mild CIN phenotype. Although the presence of CIN in HeH-B-ALL remains contro-
versial [67], the analysis is supported by the direct visualization of chromosome mis-segregation
in mitosis, and favors the presence of CIN observed by single-cell analyses such as interphase-
FISH (fluorescence in situ hybridization) in HeH-B-ALL samples [68,69]. Biochemical analysis of
dividing B-ALL blasts revealed that the condensin complex is functionally impaired in HeH-B-
ALL blasts, leading to chromosome hypocondensation, loss of centromere stiffness, and
mislocalization of the chromosomal passenger complex (CPC) that contains aurora B kinase
as its enzymatic core. Chromosome architecture defects have recently been reported by other
authors using Hi-C (high-throughput sequencing and chromatin conformation capture) analysis
of primary HeH-B-ALL samples [70] and can explain very well the poor chromosomemorphology
that clinical cytogeneticists historically encountered in metaphase spreads of HeH-B-ALL. HeH-
B-ALL blasts showed chromatid cohesion defects and loss of SAC efficiency, leading to mitotic
slippage, perhaps because aurora B kinase fails to localize to the inner centromere to protect
chromatid cohesion and allow proper SAC activity; this provides a direct link between chromo-
some misalignment and segregation defects in late mitosis. Overall, these data constitute direct
evidence for mitotic and chromosome defects in HeH-B-ALL cells and highlight the molecular
mechanisms involved in the pathogenesis of this frequent subgroup of childhood B-ALL.Whether
thesemechanisms are involved in the origins of hyperdiploidy or are the consequence of chromo-
some gains in B cell progenitors remains an open question that requires further investigation.
Concluding Remarks
An important caveat to these studies is the precise identification of causative versus consequential
defects with a view to establishing the mechanism responsible for the different aneuploidies in
B-ALL. In this sense, mouse models can provide important insights into the mechanisms
underlying mitotic defects in B cell progenitors and the effects of aneuploidy on leukemia
initiation and progression. A better understanding of the biology of hyperdiploid and hypodiploid
B-ALL subtypeswill open up new avenues for in vivomodeling aneuploidy by genetically engineering
HSPCs. This will be crucial for answering several key questions about the role of aneuploidy in
leukemia initiation and progression (see Outstanding Questions). The new data obtained from
these studies will translate into better diagnosis and treatment of patients with these common
forms of leukemia.
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